Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica

Badı́a, Xavier; Muriel, Carlos Muñiz; Gracia, Alfredo; Núñez-Olarte, Juan Manuel; Perulero, N; Gálvez, R.; Carulla, Joan; Cleeland, Charles S.

doi:10.1157/13042265

Cited by 41 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DN4 status [29], demographic data, tumour characteristics, comorbidities and previous oncologic treatment were collected at baseline; in addition to at baseline, the following data were also obtained at 8 weeks: NP characteristics, analgesic treatment, patient's evaluation of analgesic treatment effi cacy (the patient answered YES or NO to the question "Are you satisfi ed with the effi cacy of the analgesic treatment received?") and results from the following questionnaires: the Spanish version of the short form of the Brief Pain Inventory (BPI-SF) validated in cancer patients [30], the Hospital Anxiety and Depression Scale (HADS) [31], the Spanish version of the Medical Outcomes Study Sleep (MOS-Sleep) Scale validated in neuropathic patients [32] and the Spanish validated 12-item short form (SF-12) Health Survey [33]. All questionnaires used are described in the published original study [28].…”

Section: Methodsmentioning

confidence: 99%

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

et al. 2011

View full text Add to dashboard Cite

show abstract

“…[10][11][12][13] The short-form survey contains 10 scaled questions, 3 of which assess pain intensity and 7 measure functional interference. The scales are anchored between a value of 0 (no pain/interference) to 10 (maximum pain/interference).…”

Section: Methodsmentioning

confidence: 99%

Self-Reported Rates of Sleep Disturbance in Patients with Symptomatic Bone Metastases Attending an Outpatient Radiotherapy Clinic

Khan

Nguyen

et al. 2011

Journal of Palliative Medicine

View full text Add to dashboard Cite

show abstract

“…These scales have been validated for various cultures and languages, including Spanish [13,17,20]. Neuropathic pain should be identified using the tools suggested by the International Association for the Study of Pain (i.e., Lanss Pain Scale, DN4, Neuropathic Pain Questionnaire, painDETECT) [21,22].…”

Section: Multidimensional Scalesmentioning

confidence: 99%

Latin-American Guidelines for Cancer Pain Management

Lara-Solares

Olea²,

Pinos

et al. 2017

Pain Manag.

View full text Add to dashboard Cite

Practice points• Adequate pain management starts with an appropriate syndromic diagnosis based on a detailed clinical history, comprehensive physical examination and correct interpretation of additional medical tests.• Appropriate syndromic classification of pain is based on its clinical characteristics, as well as on a meticulous assessment of the intensity of pain by applying standard scales. The patient's psychosocial situation must be taken into account when attempting to optimize management and predict the response to treatment.• As with all types of chronic pain, assessment of patients with cancer pain should take into account the individual profile of the patient (age, comorbidities, functionality, previous exposure to drugs such as opioids and polypharmacy) and the type, intensity and potential clinical course of the pain. Only thus will it be possible to decide on the best approach, based on aspects such as efficacy, safety, tolerability and cost. Multimodal strategies are the most successful.• Multimodal approaches include interventional, psychological, rehabilitative and integrative therapies.• Various formulations of fentanyl have been reported for the treatment of breakthrough pain, as follows: transmucosal, intranasal, sublingual, buccal tablets and gingival. However, these formulations are not available in Latin America.• In Latin America, the WHO guidelines have proven critical for justifying to local governments the key role of opioids such as morphine and the need for an adequate supply. Nevertheless, availability of opioids in the region remains poor.• Treatment of severe pain should be with a strong opioid, in most cases with oral formulations. Other routes (intravenous, subcutaneous, spinal (epidural and intrathecal) may only be necessary in refractory cases.• Extended-release opioids (morphine, oxycodone and hydromorphone) can be supplemented with immediate-release formulations as needed. Assessment of comorbidities is essential when deciding on the best option.For reprint orders, please contact: reprints@futuremedicine.com

show abstract

Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica

Cited by 41 publications

References 0 publications

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Self-Reported Rates of Sleep Disturbance in Patients with Symptomatic Bone Metastases Attending an Outpatient Radiotherapy Clinic

Latin-American Guidelines for Cancer Pain Management

Contact Info

Product

Resources

About